Quarterly Activities Report and Appendix 4C - September 2026
Filed with ASX · · 10 pages · English
Summary by 6ix AI
The report highlights a staged program to advance the EXO-OC ovarian cancer test towards US Laboratory Developed Test readiness, with a focus on assay optimisation and clinical verification. Additionally, the company reported a strong cash position and a leadership change, with the Chairman stepping in as Executive Chair following the departure of the CEO. Financial results indicate cash on hand and net cash used in operating activities during the quarter, alongside a significant R&D tax incentive received post-period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Inoviq
- INOVIQ receives $1.782m R&D Tax Incentive Refund
- Notice of Annual General Meeting/Proxy Form
- INOVIQ Announces Leadership Change
- EXO-OC Technical Review and Commercialisation Pathway
- 2026 Annual Report
Later from Inoviq
- Board Changes
- IIQ signs EXO-OC validation agreement with Sonic Healthcare
- Initial Director's Interest Notice - A. Chapman
Follow Inoviq into a list and get an email when it puts out news.
Follow Inoviq